Fudan University: Breast Neoplasms trials

The registry lists 260 Breast Neoplasms studies with Fudan University as lead sponsor. 117 are open to participants now and 0 have results posted.

Phase 1 12Phase 2 118Phase 3 50Phase 4 6No phase 87(a study in two phases counts in both)

Studies

Page 2 of 3. Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Fudan University Shanghai Cancer Center Breast Cancer Precision Platform Series Study- Neoadjuvant TherapyRecruitingNCT05582499Phase 2
• Exploring Whether Disease-free Intervals Can Guide Endocrine Combined Targeted Therapy for ER+/HER2+ Advanced Breast Cancer (T-sunflower)Not yet recruitingNCT05577923Phase 2
• Patient-Reported Outcome and Safety Between Preoperative and Postmastectomy Radiotherapy in DIEP Flap ReconstructionRecruitingNCT05512286Not applicable
• Neoadjuvant Radiation in Locally Advanced Breast CancerRecruitingNCT05479409Phase 2
• Immune Therapy in HR-positive/HER2-negative Metastatic Breast Cancer(ENIGMA)-BCTOP-L-M02RecruitingNCT05205200Phase 2
• Medial vs. Entire Supraclavicular Lymph Node Radiation Therapy for Patients With Invasive Breast CancerRecruitingNCT05059379Phase 3
• The Association Between Radiation Dermatitis and Skin Microbiome in Breast Cancer PatientsRecruitingNCT05032768
• Single Arm Phase II Study of Fractionated Stereotatic Radiation Therapy (FSRT) for Bone Metastases in Breast CancerRecruitingNCT04947280Phase 1/2
• Stage I HER2 Positive Invasive Breast Cancer De-escalation Study(IRIS-C/D)Not yet recruitingNCT04922008Phase 2
• Effect of Huaier Granule on Adjuvant Treatment for High-risk Early-stage Triple-negative Breast CancerRecruitingNCT04790305Phase 4
• A Trial Evaluating the Efficacy of Metastasectomy in Patients With Oligo-Metastatic Breast Cancer(OMIT)RecruitingNCT04413409Not applicable
• Evaluation for the Effectiveness and Safety of Cryo-ablation in the Treatment of Early Invasive Breast CancerRecruitingNCT04334785Not applicable
• Markers to Evaluate the Efficacy of PH-based Regimen as a Neoadjuvant Therapy for Operable HER2 Positive Breast CancerRecruitingNCT04281641Not applicable
• ScreenIng of Genetic Susceptibility Genes for Breast Cancer Patients in CHinese communiTiesRecruitingNCT04265937
• A Clinical Trial of Breast Cancer Neo-adjuvant Therapy Based on Molecular Pathway in FUSCCRecruitingNCT04215003Phase 1/2
• Study Comparing 4 Cycles With 6 Cycles of TC (Docetaxel+Cyclophosphamide) Adjuvant Chemotherapy for 1-3 Lymph Node Positive ER+/HER2- Early Breast CancerRecruitingNCT03926091Phase 3
• Efficacy and Safety Study of Neoadjuvant Chemotherapy for Local Advanced Triple Negative Breast Cancer PatientsAvailableNCT01216124
• MAMMI-BB PET for Monitoring Response to Neoadjuvant Therapy in Breast CancerActive, not recruitingNCT07875244Not applicable
• PBI for Low-risk Breast CancerWithdrawnNCT07814365Not applicable
• Response-Adapted Omission of Nodal Boost In N3 Breast Cancer After Neoadjuvant TherapyWithdrawnNCT07805538Not applicable
• Comparison Between ER Loss and Triple-Negative Breast Cancer Guided by 18F-FES PET/CT in Metastatic Breast CancerActive, not recruitingNCT07316439
• EIT Evaluation of Pulmonary Ventilation With Different Ropivacaine Concentrations in Intercostal Nerve BlockadeCompletedNCT07079436Not applicable
• A ReaL World Study of DS-8201Active, not recruitingNCT06945224
• Evaluating the Efficacy of Structured Exercise Interventions in Alleviating Aromatase Inhibitor-Induced Arthralgia in Breast Cancer Survivors: a Pilot Study ProtocolActive, not recruitingNCT06754293Not applicable
• 18F-fluoroestradiol (18F-FES) PET/CT Guided First-line Treatment for HR+/HER2- Metastatic Breast Cancer PatientsCompletedNCT06655545
• Artificial Intelligence Assisted Breast Ultrasound in Breast Cancer ScreeningCompletedNCT06521788Not applicable
• Financial Navigation Program for Improving Financial Toxicity Among Breast Cancer in ChinaCompletedNCT06484140Not applicable
• Pilot Study of Financial Navigation Program for Improving Financial Toxicity Among Breast Cancer in ChinaCompletedNCT06355440Not applicable
• Initial CDK 4/6 Inhibitor Plus Endocrine Therapy Versus Initial Chemotherapy in HR Positive, HER2 Negative Unresectable or Metastatic Breast CancerCompletedNCT06344793
• Abemaciclib, Palbociclib or Dalpiciclib Combined with Endocrine Therapy As First-line Treatment in HR Positive, HER2 Negative Unresectable or Metastatic Breast CancerActive, not recruitingNCT06344780
• Positive ER Expression Assessed by 18F-FES PET/CT in the MBC with ER-negative Primary TumorCompletedNCT06344767
• Effect of ESPB on Postoperative Pain in Patients With Breast Cancer Implant ReconstructionCompletedNCT06143020Not applicable
• Pyrotinib Plus Trastuzumab and Chemotherapy in HER2+ Metastatic Breast Cancer PatientsCompletedNCT05839288
• Different Targeted Antibody-drug Conjugates For HER2 Ultra-low or No Expression Advanced Breast Cancer（GALAXY）Active, not recruitingNCT05824325Phase 1/2
• Combination of Chidamide and Fulvestrant for HR+/HER2- Breast Cancer That Has Failed Previous CDK4/6 i Adjuvant TherapyStatus unknownNCT05806047Phase 2
• Negative ER Expression Assessed by 18F-FES PET/CT in the MBC With ER-positive Primary TumorCompletedNCT05797987
• Monitoring Response to Neoadjuvant Chemotherapy in Breast Cancer Using Ultrafast DCE-MRIStatus unknownNCT05744518
• A Trial Exploring the Opportune Administration of Nab-paclitaxel in the First Line Treatment, Camrelizumab Combined With Nab-paclitaxel and Famitinib, of TNBC.Status unknownNCT05670925Phase 2
• Feasibility in Identification of Breast Cancer Candidates for Elimination of Axillary SurgeryCompletedNCT05663021Not applicable
• Real-world Effectiveness and Safety Study of T-Dxd in Chinese Metastatic Breast CancerStatus unknownNCT05594082
• Dalpiciclib, Fulvestrant, Trastuzumab and Pertuzumab in HR Positive, HER2 Positive Metastatic Breast CancerActive, not recruitingNCT05574881Phase 1/2
• Pyrotinib Plus Trastuzumab Versus Pertuzumab Plus TrastuzumabCompletedNCT05572645
• The Rechallenge of ADCs in MBC PatientsActive, not recruitingNCT05571618
• Health-promoting Lifestyle in a Genetic Counseling ClinicCompletedNCT05545254
• Incidence and Prognostic Significance of HER-2 Status Discordance Between Primary Breast Cancer and Paired Recurrent/Metastatic LesionsCompletedNCT05510037
• MammaPrint Value for Pre-menopausal Breast Cancer PatientsActive, not recruitingNCT05474391
• A Clinical Study of the Efficacy and Safety of Chidamide in Combination With Camrelizumab and Carboplatin or Capecitabine in the Second and Third Line Treatment of Relapsed/Metastatic Triple-negative Breast CancerStatus unknownNCT05438706Phase 2
• Comparison of Dexamethasone Alone vs in Combination With Pericardium 6 (P6) Electrical Stimulation or Granisetron in the Prevention of Postoperative Nausea and Vomiting in Patients Undergoing Breast Cancer SurgeryCompletedNCT05408676Not applicable
• Weekly Utidelone in HER2-negative Inoperable Locally Advanced or Metastatic Breast CancerStatus unknownNCT05403333Phase 2
• Detection and Analysis of MBC With Heterogeneous ER ExpressionCompletedNCT05392985
• Sintilimab and Bevacizumab Biosimilar Combined With PLD in mTNBCStatus unknownNCT05386524Phase 2
• Real-world Study of UTD1 in Chinese Advanced Breast CancerCompletedNCT05386511
• Pyrotinib Rechallenge in Her2-positive Metastatic Breast Cancer Pretreated With Pyrotinib and TrastuzumabStatus unknownNCT05346861Phase 3
• HER2-positive Breast Cancer Project Initiated by InvestigatorsStatus unknownNCT05346328Phase 2
• Cryoablation Combined With Tirelizumab and Bevacizumab in Liver Metastatic TNBC Patients Failed by Multiline TherapyStatus unknownNCT05303038Phase 2
• Serratus Anterior Plane Block for Modified Radical Mastectomy: Double-point VS Single-pointCompletedNCT05299021Not applicable
• Induction of Cisplatin/Nab-paclitaxel/Pembrolizumab Followed by Olaparib/Pembrolizumab Maintenance in mTNBC PatientsStatus unknownNCT05174832Phase 2
• Axillary Sentinel or Targeted Lymph Node Biopsy Alone After Neoadjuvant Chemotherapy in Node-positive Breast CancerStatus unknownNCT05141630Phase 2
• RWE About QOL and Compliance of Patients With OFS in ChinaCompletedNCT05122377
• Neoadjuvant With Trastuzumab, Pyrotinib Plus Palbociclib and Fulvestrant in HER2-positive, ER-positive Breast CancerStatus unknownNCT05076695Phase 2
• ARX788 in HER2-positive Breast Cancer Patients With Brain MetastasesStatus unknownNCT05018702Phase 2
• ARX788 in Breast Cancer With Low Expression of HER2Status unknownNCT05018676Phase 2
• Prediction of 18F-FES-PET/CT Parameters on Palbociclib Combined With ETCompletedNCT04992156
• Tislelizumab in Combination With Eribulin for Patients With Metastatic Previously heaviLy-treAted TriplE-negative Breast Cancer：A Prospective Multiple-center Phase II StudyStatus unknownNCT04913571Phase 2
• Pyrotinib Plus Vinorelbine Versus Lapatinib Plus CapecitabineCompletedNCT04850625
• Albumin-bound Paclitaxel Combination With Capecitabine Versus Capecitabine Monotherapy in Paclitaxel/Docetaxel-resistant Advanced Breast CancerStatus unknownNCT04780347Phase 2
• Study on the Value of Non-invasive Dual-Pet Information in Subtype of Metastatic Breast CancerStatus unknownNCT04758416
• Guided Treatment Based on Mini-PDX in Metastatic Triple Negative Breast CancerStatus unknownNCT04745975Phase 2
• A Phase II Study to Explore the Safety, Tolerability, and Preliminary Antitumor Activity of Sitravatinib Plus Tislelizumab or Combination With Nab-paclitaxel in Patients With Locally Recurrent or Metastatic Triple Negative Breast Cancer (TNBC)Active, not recruitingNCT04734262Phase 2
• Prepectoral and Subpectoral Implant-based Breast ReconstructionActive, not recruitingNCT04688697Not applicable
• Pyrotinib Combined With Brain Radiotherapy in Breast Cancer Patients With Brain MetastasesStatus unknownNCT04582968Phase 1/2
• Eribulin in mTNBC PatientsCompletedNCT04541420
• First-line Nab-paclitaxel Plus Cisplatin Plus Camrelizumab in mTNBC PatientsCompletedNCT04537286Phase 2
• Treatment After Palbociclib-containing RegimensCompletedNCT04517318
• Pyrotinib Plus Vinorelbine in HER2+ Metastatic Breast Cancer PatientsCompletedNCT04517305
• Eribulin Plus Cisplatin Versus Gemcitabine Plus Cisplatin in Triple Negative Breast Cancer (TNBC)Status unknownNCT04517292Phase 2
• Combination of HX008 And Niraparib in GErm-line-mutAted Metastatic Breast CancerCompletedNCT04508803Phase 2
• Clinical Study of Imaging Genomics Based on Machine Learning for BCIGStatus unknownNCT04461990
• Evaluating the Clinical Value of Traditional Chinese Medicine in the Adjuvant Therapy of Triple-negative Breast CancerStatus unknownNCT04403529Phase 3
• An Umbrella Trial Based on Molecular Pathway for Patients With Metastatic TNBC.Active, not recruitingNCT04395989Phase 2
• Stage I HER2 Positive Invasive Breast Cancer De-escalation Study(IRIS)Active, not recruitingNCT04383275Phase 2
• Molecularly Targeted Umbrella Study in Luminal Advanced Breast CancerStatus unknownNCT04355858Phase 2
• NX in Luminal B Breast Cancer Patients After Neoadjuvant ChemotherapyStatus unknownNCT04307147Phase 3
• A Phase II Study of Triple-negative Breast Cancer Brain Metastases.Status unknownNCT04303988Phase 2
• A Study to Evaluate Gemcitabine Plus Cisplatin in the Treatment of TNBC Patients Following Neoadjuvant ChemotherapyStatus unknownNCT04297267Phase 2
• Carboplatin Intensified Chemotherapy for TRIple NEgative Breast Cancer(CITRINE)Active, not recruitingNCT04296175Phase 3
• Oral Vinorelbine or Capecitabine Combined With Trastuzumab as Adjuvant Treatment for Patients With Lymph Node Negative, HER-2 Positive and Small Tumor Size Breast Cancer (ORCHID)CompletedNCT04296162Phase 2
• Study Comparing EC-T Verses PCb in the Adjuvant Chemotherapy of Non-triple Negative Breast CancerActive, not recruitingNCT04193059Phase 3
• Chidamide Combined With Cisplatin for Relapsed or Metastatic Triple-negative Breast CancerStatus unknownNCT04192903Phase 2
• A Trial of Camrelizumab in Combination With Nab-paclitaxel and Famitinib as a First Line Treatment in Patients With Unresectable Locally Advanced or Metastatic Immunomodulatory Triple Negative Breast Cancer(FUTURE-C-PLUS)Status unknownNCT04129996Phase 2
• Adjuvant 6 Cycles of Docetaxel and Cyclophosphamide or 3 Cycles of Cyclophosphamide/Epirubicin/Fluorouracil Followed by 3 Cycles of Docetaxel Versus 4 Cycles of Epirubicin and Cyclophosphamide Followed by Weekly Paclitaxel in Operable Breast Cancer (MASTER)CompletedNCT04127019Phase 3
• FSRT in Breast Cancer Patients With Brain MetastasesStatus unknownNCT04061408Phase 2
• Study Comparing Paclitaxel Plus Carboplatin Versus Anthracyclines Followed by Docetaxel as Adjuvant Chemotherapy for Triple Negative Breast Cancer (PATTERN)CompletedNCT04031703Phase 3
• Patient Report Outcome-Reconstruction and Oncoplastic CohortStatus unknownNCT04030845
• 18F-FES PET/CT's Additional Clinical Value in ER+ BCCompletedNCT04006626
• Dual Anti-HER2 Therapy (Lapatinib and Trastuzumab) Plus Chemotherapy in HER2-positive MBCCompletedNCT04001634
• Pyrotinib in Combination With Capecitabine in Patients With Trastuzumab-resistant HER2-positive Advanced Breast CancerStatus unknownNCT04001621Phase 2
• Cardiac Safety and Efficacy for Early-stage Breast Cancer Patients Treated With Pegylated Liposomal Doxorubicin（PLD)Status unknownNCT03949634Phase 3
• Real World Study of Lapatinib Among Metastatic Breast Cancer PatientsCompletedNCT03894410
• Hypofractionated Vs Conventional Fractionated Postmastectomy Radiotherapy for High Risk Breast CancerCompletedNCT03856372Not applicable